DATATRAK Highlighted at SAS Users Group International as a Leading EDC Provider Participants get firsthand demonstration of the benefits in linking DATATRAK EDC(R) and SAS Drug Development CLEVELAND, April 11 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: "DATA"), the leading and most experienced Application Service Provider (ASP) in the Electronic Data Capture (EDC) industry, today announced that the Company has been highlighted as a leading EDC provider in an announcement addressing the 30th Annual SAS Users Group International ("SUGI") meeting held in Philadelphia, with attendance by more than 3,000 SAS users from around the world. As detailed in a separate announcement located on the SAS website at http://www.sas.com/, nearly a dozen firms have turned to SAS Drug Development for superior data warehousing, analytic, reporting and exploring technologies that help turn vast amounts of data into the kind of intelligence demanded by decision makers who need to respond quickly with the right decisions. This announcement from SAS is significant for several reasons. It identifies leading pharmaceutical companies who have elected to pursue SAS Drug Development as a corporate strategy for clinical trials information processing. Momentum for SAS Drug Development is clearly building, and more life sciences firms will soon pursue SAS Drug Development as a strategy that solves many internal process issues and makes information transfer and management more efficient. Firms already using SAS software in their organizations include every FORTUNE Global 500(R) Life Sciences Company and nearly 600 pharmaceutical companies and divisions worldwide. SAS Drug Development is linked directly to DATATRAK EDC(R) in order to provide heretofore unavailable efficiencies in clinical data collection, surveillance and management. There are two ways in which "DATATRAK Aware -- Powered by SAS" can be purchased by clients. Any client can receive all the advantages of EDC linked directly with SAS Drug Development on a trial-by-trial basis through an incremental data item fee following the standard DATATRAK business model. In this situation, no enterprise license of SAS Drug Development is required by the clinical trial sponsor and no capital is required upfront. This approach accommodates companies of any size, provides complete flexibility, and can be activated at will. Alternatively, customers who have already purchased SAS Drug Development can further streamline their clinical trials operations by taking advantage of the direct link to EDC. At that point, all that is required is a connection between DATATRAK EDC(R) and the resources already devoted to SAS Drug Development. For customers who have already purchased an enterprise SAS Drug Development license, the incremental data item fee is waived. These customers can immediately magnify the total value of SAS Drug Development because their global clinical trials data is fed directly into their repository from an automatic link with EDC that has already been prepared by DATATRAK and SAS. "We are currently in dialogue with many different clients regarding the Aware offering that fit within both implementation categories," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "Our co-marketing efforts with SAS have identified clients who use EDC and desire a repository strategy, as well as clients who have purchased SAS Drug Development and are attracted to the potential of direct linkages with EDC in order leverage an investment and strategic direction they have already elected. The ability to offer analyzable SAS datasets updated automatically as often as every 24 hours and available through a thin client anywhere in the world enables the closest to the maximum efficiency for this industry that one can imagine." About SAS SAS is the market leader in providing a new generation of business intelligence software and services that create true enterprise intelligence. SAS solutions are used at more than 40,000 sites -- including 96 of the top 100 companies on the FORTUNE Global 500(R) -- to develop more profitable relationships with customers and suppliers; to enable better, more accurate and informed decisions; and to drive organizations forward. SAS is the only vendor that completely integrates leading data warehousing, analytics and traditional BI applications to create intelligence from massive amounts of data. For nearly three decades, SAS has been giving customers around the world The Power to Know(R). Visit us at http://www.sas.com/. About DATATRAK International DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(R) and related services to the pharmaceutical, biotechnology, and medical device industries. DATATRAK EDC(R) was developed in order to deliver clinical research data from investigative sites to clinical trial sponsors faster and more efficiently than conventional, manual methods. DATATRAK EDC(R) can be deployed worldwide in either a distributed platform using laptop computers or in a centralized environment using the Internet. DATATRAK EDC(R) software and its earlier versions have successfully supported many international clinical studies involving thousands of clinical research sites and encompassing tens of thousands of patients in over 46 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 14 separate drugs that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio and Bonn, Germany. Its common stock is listed on the Nasdaq Stock Market under the symbol "DATA." Visit the DATATRAK International, Inc. web site at http://www.datatrak.net/ or http://www.datatraknet.de/. Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. Factors that may cause actual results to differ materially from those in the forward-looking statements include the ability of the Company to absorb corporate overhead and other fixed costs in order to successfully market the DATATRAK EDCO software; the development and fluctuations in the market for EDC technology; continued unreliability of the Internet infrastructure; the degree of the Company's success in obtaining new contracts; the timing of payments from customers and the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; dependence on key personnel; governmental regulation; the early stage of the Company's EDC business and operations; and general economic conditions. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. DATASOURCE: DATATRAK International, Inc. CONTACT: Jeffrey A. Green, Pharm.D., FCP, President and Chief Executive Officer, +1-440-443-0082, ext. 112, or Terry C. Black, Chief Financial Officer, +1-440-443-0082, ext. 110, both of DATATRAK International, Inc.; or Neal Feagans, Investor Relations of Feagans Consulting, Inc., +1-303-449-1184, for DATATRAK International, Inc. Web site: http://www.datatraknet.com/ http://www.datatraknet.de/ http://www.sas.com/

Copyright